|
DecImmune Therapeutics is developing a novel monoclonal antibody, DeciMab™, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. |
10.3.2014DecImmune Therapeutics Awarded $3 Million in SBIR Phase IIB Funding 04.22.2013DSM and DecImmune Sign Agreement to Develop N2 Pathway Blocking Antibody |
